Iterum Therapeutics Q2 2024 Adj. EPS $(0.23) Beats $(0.45) Estimate; Cash, Cash Equivalents And Short-Term Investments Were $11.7M Will Be Sufficient To Fund Its Operations Into 2025
Portfolio Pulse from Benzinga Newsdesk
Iterum Therapeutics reported a Q2 2024 adjusted EPS of $(0.23), beating the estimate of $(0.45). The company also announced that its cash, cash equivalents, and short-term investments of $11.7M will be sufficient to fund operations into 2025.
August 14, 2024 | 11:07 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Iterum Therapeutics reported a Q2 2024 adjusted EPS of $(0.23), beating the estimate of $(0.45). The company also announced that its cash, cash equivalents, and short-term investments of $11.7M will be sufficient to fund operations into 2025.
Iterum Therapeutics' better-than-expected EPS and sufficient cash reserves to fund operations into 2025 are positive indicators for the company's financial health, likely boosting investor confidence and short-term stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100